Citation

Jiang J, Wolters JE, van Breda SG, Kleinjans JC, de Kok TM. Expert Opin. Drug. Metab. Toxicol. 2015; 11(10): 1523-1537.

Affiliation

Maastricht University, GROW School for Oncology and Developmental Biology, Department of Toxicogenomics , Maastricht , The Netherlands +31 43 3881090 ; +31 43 3884146 ; j.jiang@maastrichtuniversity.nl.

Copyright

(Copyright © 2015, Informa Healthcare)

DOI

10.1517/17425255.2015.1065814

PMID

26155718

Abstract

INTRODUCTION: Due to its complex mechanisms and unpredictable occurrence, drug-induced liver injury (DILI) complicates drug identification and classification. Since species-specific differences in metabolism and pharmacokinetics exist, data obtained from animal studies may not be sufficient to predict DILI in humans. Areas covered: Over the last few decades, numerous in vitro models have been developed to replace animal testing. The advantages and disadvantages of commonly used liver-derived in vitro models (e.g., cell lines, hepatocyte models, liver slices, three-dimensional (3D) hepatospheres, etc.) are discussed. Toxicogenomics-based methodologies (genomics, epigenomics, transcriptomics, proteomics and metabolomics) and next-generation sequencing have also been used to enhance the reliability of DILI prediction. This review presents an overview of the currently used alternative toxicological models and of the most advanced approaches in the field of DILI research. Expert opinion: It seems unlikely that a single in vitro system will be able to mimic the complex interactions in the human liver. Three-dimensional multicellular systems may bridge the gap between conventional 2D models and in vivo clinical studies in humans and provide a reliable basis for hepatic toxicity assay development. Next-generation sequencing technologies, in comparison to microarray-based technologies, may overcome the current limitations and are promising for the development of predictive models in the near future.

Language: en